Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Omniture: Stalking Visitors Legitimately
- It's not the least bit creepy to find out exactly who your users are, which sites they visit, or what kind of pants they wear – it's solid business tactics. Omniture helps the biggest names on the internet track their traffic and give their customers more of what they like.
- Videos 2008-04-07
- Materials Buyers Guide.(Directory)
- The Materials Buyers Guide section is arranged alphabetically. Wherever pertinent, the products are grouped under major headings that include specific functions or variations of materials. Separate sections start on page 83 for the Machinery Buyers Guide, page 175 for the Components & Accessories Buyers Guide and...
- Research articles 2002-10-01
- Materials Buyers Guide.(Buyers Guide)
- Materials Buyers Guide section is arranged alphabetically. Wherever pertinent, the products are grouped under major headings that include specific functions or variations of materials. Separate sections start on page 55 for the Machinery Buyers Guide and page 223 for the Suppliers/Services Buyers Guide. One General Index...
- Research articles 2000-10-01
- Dos and Don'ts to Survive Audit
- There are certain dos and don'ts for making it through an Internal Audit discussed in the article like the things that are necessary in audit process are : Respond timely to every communication from the IRS -- even if you only request more time. No response from you...
- White papers 2003-01-01
Additional Resources
- J&J to Slash 7,000 to 8,000 Jobs
- By Ransdell PiersonNEW YORK (Reuters) - Johnson & Johnson plans to cut up to 7 percent of its workforce in order to generate cost savings needed to finance increasingly costly drug research and to weather future challenges, the diversified healthcare company said on Tuesday.J&J said the planned restructuring will eliminate...
- News items 2009-11-03
- J&J Slashing Workforce
- By Ransdell PiersonNEW YORK (Reuters UK) - Johnson & Johnson JNJ plans to cut up to 7 percent of its workforce in order to generate cost savings needed to finance increasingly costly drug research and to weather future challenges, the diversified healthcare company said on Tuesday.J&J said the planned restructuring...
- News items 2009-11-03
- An Explanation for J&J's Ad Agency Switch: It's Not About the Creativity
- Johnson & Johnson's decision to consolidate its $110 million drug advertising business at two agency holding companies, WPP and InterPublic, raises an interesting question: If it's supposed to be a consolidation, why two and not one? Here's one possible answer: The companies are being pitted against each other in an...
- Blog posts 2008-11-05
- J&J's Red Cross Suit Sent (Mostly) Packing
- Johnson & Johnson might have had better luck had it decided to introduce a line of baby itching powder or Band-Aids guaranteed to make the "ouch" even worse. As it stands, though, its decision last August to sue the Red Cross over use of the instantly recognizable symbol they both...
- Blog posts 2008-05-19
- The Bad News Behind J&J's Good Q3 Earnings and Why Pfizer is Kicking Itself as a Result
- Johnson & Johnson announced its third quarter earnings and reported good news: Sales were up year on year 6.4 percent to $15.9 billion. That topline number illustrates two things: how bad news can be concealed inside a diversified pharma play; and how dumb Pfizer was to sell J&J its consumer...
- Blog posts 2008-10-14
- J. Crew: One-Upping the Gap in Quality, Style, and Agility
- With savvy PR and an agile product line, J. Crew has snagged a good chunk of the Gap's market — and even its CEO. Giant: The Gap Shadow Success: J. Crew The Gap market cap: $11.7 billion; revenues: $14.2 billion J. Crew market...
- Articles 2009-06-10
- J&J and Risperdal: New Claims of Kickbacks and Fraudulent Marketing
- The news on Risperdal continues to get worse for Johnson & Johnson and its antipsychotic unit, Janssen Pharmaceuticals. Texas officials filed suit against the company alleging Medicaid fraud, kickbacks and improper marketing of the drug to children and the poor in that state. J&J denies the claims. ...
- Blog posts 2008-12-17
- J&J's Troubles Gather Faster Than It Can Cut Jobs to Deal With Them
- Employees of Johnson & Johnson should look at today's Q4 earnings announcement and prepare for layoffs at the company. Although J&J increased its net income by 14.3 percent to $2.7 billion, everything else on its income statement was down: Sales fell 4.9 percent to $15.2 billion, indicating...
- Blog posts 2009-01-20
- J&J Fined $5,000 Per Sales Rep Visit for Risperdal Mismarketing
- How bad could that Texas lawsuit against Johnson & Johnson for mismarketing Risperdal be? Try $5,000 per visit of a sales rep to a doctor. That was the formula used in a West Virginia state court case in which the state attorney general sued J&J and its...
- Blog posts 2009-03-03
- Why J&J "Deselected" 900 Reps Despite Sales Growth
- Johnson & Johnson's Ortho McNeil/Janssen unit is in the process of laying off about 900 staffers, according to Dow Jones Newswires. Sales and profits at J&J are both up overall. Sales went up from $61 billion to $63.4 billion last year, profit was up from $10.5 billion...
- Blog posts 2009-04-10
- J&J vs. Merck and Schering: Who Is Most Desperate in This Bizarre Love Triangle?
- Nobody wants to say anything about the great Remicade tug of war that has broken out between Johnson & Johnson and the soon-to-be-merged Merck and Schering-Plough. A look at the Q1 2009 numbers suggest that each member of this trio has their own reasons to be quietly...
- Blog posts 2009-04-24
- J&J Quarterly Sales Miss Estimates, Shares Fall
- By Ransdell Pierson and Lewis KrauskopfNEW YORK (Reuters) - Johnson & Johnson JNJ posted weaker-than-expected quarterly revenue on Tuesday as sales of prescription drugs and heart stents disappointed, sending its shares down 2.4 percent.While third-quarter profit topped analyst forecasts, that was largely because of cost cuts and lower taxes."I think...
- News items 2009-10-13
- J&J Settles Fatal Patch Cases, So Why Is This Thing Still on the Market?
- Johnson & Johnson has paid $68 million to settle hundreds of cases brought by women who used the Ortho Evra birth control patch. The settlements raise a question: Why is this patch still on the market when it is now well-established that its risk of causing fatal blood clots is...
- Blog posts 2008-10-10
- Medicis Squeezed in Vanity Pharma Death Match vs. Allergan and J&J
- Medicis may find itself on the losing side of the vanity pharma death match now that Johnson & Johnson has waded in with what will soon be a full suite of silicone breast implants, wrinkle fillers and botulinum toxin line smoothers. J&J on Monday agreed to acquire implant maker Mentor...
- Blog posts 2008-12-02
- J&J Profit Beats Estimates, But Sales Fall Short
- By Ransdell Pierson and Lewis Krauskopf NEW YORK (Reuters) - Johnson & Johnson JNJ posted weaker-than-expected quarterly revenue on Tuesday as sales of prescription drugs and cardiac stents disappointed, sending its shares down more than 2 percent. While third-quarter profit topped analyst forecasts, that was largely because of cost cuts...
- News items 2009-10-13
- A Q&A With J&J's Joe Natale on Why Pharma Stays Stuck in the Web's Past
- Pharmaceutical company web sites tend to have one thing in common: They almost never allow consumers to interact with each other or the company. That's a stark contrast to companies in every other consumer-oriented business, where brands are desperate to get consumers hooked on their bulletin boards, web-hosting services and...
- Blog posts 2008-10-20
- << Previous
- page 1 of 1
- Next >>
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
